Device Trial Radar · NCT05243810
EPC Silver Wound Gel (EPC-123) Feasibility Study in the Management of Mildly Infected Diabetic Foot Ulcers
Last checked: Nov 20, 2026Latest source record: Sep 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5
Actual
Start
Nov 28, 2022
Primary completion
Sep 21, 2023
Study completion Sep 21, 2023
Sponsor
- Lead sponsor
- Exciton Technologies Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Feb 17, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this single-arm feasibility study is to investigate the safety and impact of the topical EPC Silver Wound Gel (EPC-123) in the management of diabetic foot ulcer wounds not progressing under the current standard of care.
Conditions
- Diabetic Foot Ulcer
- Non-healing Diabetic Foot Ulcer
- Diabetic Foot Infection
Interventions
EPC Silver Wound GelDevice
Re-application of EPC-123 will occur within 48 hours of the initial application. Secondary dressings will be selected at the discretion of the clinician or home care provider, based upon best practice guidelines for moisture management and will consist of a selection between the following secondary dressings: Mesorb® (Molnyke), Gauze, Cling (self-adherent gauze), or MediporeTM (3M). Application of EPC-123 will be executed at the Lawson Health Research Institute every second visit, where interim applications will be facilitated by home care. To support home care applications, a study kit will be provided to home care professionals inclusive of the EPC Silver Wound Gel, secondary dressings required, and instructions for removal/re-application.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of intervention-related adverse events collected throughout the trialTime frame: Up to 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Lawson Health Research Institute
London, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.